DCL0023 · Research use only

A1I4R2C18-2 · Formulation & Performance

A1I4R2C18-2 · DCL0023 · Patent evidence

Formulation & Performance

Four-component formulation

Component	DC Chemicals product	Molecular weight	Molar proportion	Mass contribution per 1 µmol total lipid
A1I4R2C18-2	DCL0023	1010.64	50%	0.505320 mg
DSPC	DC57005	790.15	10%	0.079015 mg
Cholesterol	DCD-041	386.65	38.5%	0.148860 mg
DMG-PEG	Not uniquely mapped	Not specified in the patent	1.5%	Requires the PEG-lipid molecular weight

Reported: test lipid:cholesterol:DSPC:DMG-PEG = 50:38.5:10:1.5 mol%. The table above reorders DSPC and cholesterol while retaining their original assignments. The molar proportions total 100%. Molecular weights for the test lipid are calculated from the verified neutral structure; mass contributions are calculations, not measured values.

The source names DMG-PEG without a PEG chain length or molecular weight. It cannot be uniquely assigned to DMG-PEG2000. Complete mass percentages require a defined PEG-lipid molecular weight.

Component mass calculator

Defaults follow Example 6. Enter the molecular weight of your selected PEG-lipid before calculating the complete formulation. DMG-PEG2000 (DC40169) may be selected as a separate commercial research option using MW 2507; this choice is not identified in the patent.

Total lipid amount (µmol)

Component	Mass (mg)	Mass %
A1I4R2C18-2	—	—
DSPC	—	—
Cholesterol	—	—
DMG-PEG	—	—

Enter the PEG-lipid molecular weight to calculate mass fractions.

Study conditions and formulation parameters

Parameter	Reported information	Source
Cargo	Luciferase mRNA	Example 10
Model	C57BL/6 mice, 6–8 weeks old	Example 10
Route	Intravenous, tail vein	Example 10
mRNA dose	5 µg per mouse	Example 10
Endpoint	6 hours after formulation administration; bioluminescence imaging	Example 10
Test lipid : nucleic acid mass ratio	11:1 (w/w); this is not an N/P ratio	Example 6
N/P ratio	Not reported	Example 6
Preparation context	Ethanolic lipid phase and citrate-buffered aqueous RNA phase; aqueous:organic volume ratio 3:1; buffer exchange into PBS	Example 6
Buffer	25 mM citrate, pH 3.0, during mixing	Example 6
Particle size / PDI / zeta potential / encapsulation	No compound-specific measurements reported for these two lipids in Table 1	Example 6, Table 1
pKa	Not reported for this compound	Supplied patent

Intravenous mRNA expression in mice

Lipid	Splenic luminescence intensity	Study context
A1I4R2C18-2	3.18 × 10³	IV luciferase mRNA, 5 µg per mouse, 6-hour endpoint
A1I4R13C18-2	2.85 × 10⁴	Same reported screen and formulation framework

Reported values transcribed from Table 3, printed page 27 (PDF page 29). The table labels the endpoint as splenic luminescence intensity but does not specify its numerical unit, replicate count, error bars or statistical significance for these rows.

A1I4R13C18-2 has an approximately 8.96-fold higher tabulated reading than A1I4R2C18-2 (28,500 ÷ 3,180; calculated). This arithmetic comparison does not establish statistical significance or a general advantage across routes, doses or cargos.

What these data establish

The patent provides compound-specific reporter-expression results after intravenous administration. It does not establish selective spleen targeting, a therapeutic outcome, or efficacy in humans for either product.

Cell data and tolerability

No compound-specific cytotoxicity, serum chemistry, organ histology, repeated-dose safety or therapeutic-index results were identified for A1I4R2C18-2 in the supplied patent. No low-toxicity claim is assigned. The intramuscular, immunization and other data for similarly named compounds are not attributed to this product.

Original patent table

Original Table 3 excerpt showing A1I4R2C18-2 and A1I4R13C18-2 structures and splenic luminescence values — WO2023142167A1, Table 3, printed page 27: original header and six adjacent rows, including both requested compounds. Original Chinese labels are retained in the source image; the data are transcribed in English above. No animal photograph is provided for these exact compounds.

References

Liu Z, Chen Y, He Z, Yue Z. Cationic lipid analog, and composition and use thereof. WO2023142167A1. Applicant: Guangzhou Lide Biomedicine Technology Co Ltd. Published 3 August 2023. Read the original patent. Compound identities: Example 2 and Table 3; formulation: Example 6 (printed page 19); intravenous mouse study: Example 10 (printed page 20), Table 3 (printed page 27). Printed page numbers refer to the supplied publication; PDF pages are two pages higher.